Volume 18, Number 4—April 2012
Dispatch
Human Parvovirus 4 Infection, Cameroon
Myriam Lavoie, Colin P. Sharp, Jacques Pépin
, Christopher Pennington, Yacouba Foupouapouognigni, Oliver G. Pybus, Richard Njouom, and Peter Simmonds
, Christopher Pennington, Yacouba Foupouapouognigni, Oliver G. Pybus, Richard Njouom, and Peter SimmondsTable 1
Prevalence of human parvovirus 4 by patient characteristics, Cameroon, 2009*
| Characteristic | No. virus positive/ no. tested (%) | p value |
|---|---|---|
| Age, y | 0.04 | |
| 60–64 | 32/125 (26) | |
| 65–69 | 13/96 (14) | |
| 70–74 | 17/103 (17) | |
| >75 | 17/127 (13) | |
| Sex | 0.15 | |
| M | 25/178 (14) | |
| F | 54/273 (20) | |
| HCV serologic results | 0.61 | |
| Negative | 29/178 (16) | |
| Positive | 47/252 (19) | |
| Anti-HBcAg | 1.00 | |
| Negative | 3/21 (14) | |
| Positive | 76/430 (18) | |
| Treponemal antibodies | 0.06 | |
| Absent | 28/119 (24) | |
| Present | 51/332 (15) | |
| Intravenous treatment for malaria | 0.04 | |
| No | 29/216 (13) | |
| Yes | 50/235 (21) | |
| Intravenous treatment for other diseases | 0.93 | |
| No | 42/239 (18) | |
| Yes | 37/212 (17) | |
| No. past intravenous treatments | 0.38 | |
| 0 | 12/88 (14) | |
| 1–3 | 33/206 (16) | |
| >4 | 25/116 (22) | |
| Unknown | 9/41 (22) | |
| Tuberculosis | 0.04 | |
| No | 72/433 (17) | |
| Yes, treated with oral drugs only | 4/12 (33) | |
| Yes, treatment included streptomycin | 3/6 (50) | |
| Transfusion | 0.09 | |
| No | 76/408 (19) | |
| Yes | 3/43 (7) | |
| Depo-Provera injections† | 0.006 | |
| No | 50/268 (19) | |
| Yes | 4/5 (80) | |
| Scarifications | 0.88 | |
| No | 30/165 (18) | |
| Yes | 49/286 (17) | |
| Vaccine scar, left arm | 0.005 | |
| Absent | 17/53 (32) | |
| Present | 61/397 (15) | |
| Vaccine scar, right arm | 0.76 | |
| Absent | 27/165 (16) | |
| Present | 51/284 (18) | |
| Circumcision (males only) | 0.74 | |
| Medical | 9/73 (12) | |
| Traditional | 16/105 (15) | |
*HCV, hepatitis C virus, HBcAg, hepatitis B core antigen.
†Pharmacia & Upjohn Company, New York, NY, USA.
